Cytosorbents Corporation (CTSO) Stock Forecast
CTSO analyst forecast
as of October 18, 2026- Analyst consensus
- Hold 3.00 / 5 from 1 analysts
- Price target
- $47.50 average of analyst targets
- Upside to target
- +1,055.7% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.90
- 52-week range
- $3.06 – $17.00
CTSO analyst ratings
1 analystsNumber of analysts at each rating.
CTSO price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CTSO earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.90 | −$1.00 | −$0.80 | −$1.00 | +10.0% | 2 |
| Current fiscal year (2026) | −$4.40 | −$4.40 | −$4.40 | −$2.60 | −69.2% | 2 |
| Next fiscal year (2027) | $0.00 | $0.00 | $0.00 | — | — | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CTSO revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $9.9M | $9.7M | $10.1M | +4.5% | 2 |
| Current fiscal year (2026) | $38.9M | $38.2M | $39.6M | +4.9% | 2 |
| Next fiscal year (2027) | $44.2M | $41.2M | $47.1M | +13.6% | 2 |
CTSO EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CTSO revenue: reported and forecast
CTSO EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.70 | −$0.70 | −$0.70 | −$0.90 | −$0.90 | +28.6% | 0 up · 2 down |
| Current fiscal year (2026) | −$3.70 | −$3.70 | −$3.70 | −$4.40 | −$4.40 | +18.9% | 0 up · 2 down |
| Next fiscal year (2027) | −$1.60 | −$0.20 | −$0.20 | −$0.20 | $0.00 | −100.0% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CTSO earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CTSO beat in 6 of 12.
What analysts expect from CTSO
1 analysts cover Cytosorbents; their consensus rating is hold (3.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $47.50, 1,055.7% above the latest close of $4.11. Analysts expect earnings of −$4.40 per share for 2026, −69.2% from a year earlier. For 2027 the average estimate is $0.00 per share on revenue of $44.2 million. Cytosorbents beat the EPS estimate in 6 of the last 12 quarters.
Related: CTSO income statement, CTSO key metrics, CTSO chart. See the CTSO stock overview for the latest quote and news.
CTSO forecast FAQ
What is Cytosorbents's price target?
The average analyst price target for Cytosorbents is $47.50, 1,055.7% above the latest close of $4.11.
Is Cytosorbents a buy, hold or sell?
Of 1 analysts covering Cytosorbents, 0 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
What is Cytosorbents's EPS forecast?
Analysts forecast −$4.40 per share for 2026 (range −$4.40 to −$4.40); for 2027 the estimate is $0.00.
What is Cytosorbents's revenue forecast?
The average revenue estimate for 2026 is $38.9 million, growth of 4.9%; for 2027 it is $44.2 million.
When does Cytosorbents report earnings?
Cytosorbents is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 after the market closes; the EPS estimate is $-0.90.
Does Cytosorbents usually beat earnings estimates?
Cytosorbents reported EPS at or above the analyst estimate in 6 of the last 12 quarters.